Efficacy and safety of alemtuzumab in a real-life cohort of patients with multiple sclerosis
Sign Up to like & getrecommendations! Published in 2019 at "Journal of Neurology"
DOI: 10.1007/s00415-019-09272-6
Abstract: BackgroundNo postmarketing randomised clinical trials are available about alemtuzumab, and real-world data are limited. We aimed to analyse the efficacy and safety of alemtuzumab in a single-centre cohort of patients with relapsing–remitting MS.MethodsPatients who took… read more here.
Keywords: alemtuzumab real; efficacy safety; cohort patients; safety alemtuzumab ... See more keywords
Safety of alemtuzumab in a nationwide cohort of Finnish multiple sclerosis patients
Sign Up to like & getrecommendations! Published in 2021 at "Journal of Neurology"
DOI: 10.1007/s00415-021-10664-w
Abstract: Alemtuzumab is an effective disease-modifying therapy (DMT) for highly active multiple sclerosis (MS). However, safety concerns limit its use in clinical practice. To evaluate the safety of alemtuzumab in a nationwide cohort of Finnish MS… read more here.
Keywords: alemtuzumab nationwide; safety; safety alemtuzumab; cohort ... See more keywords